Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 6/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5697661 | 1.00 | KIF11 (0.50) | KIF11GSRGRM8GRM6GRIN2D | |
| SCHEMBL14420362 | 1.00 | KIF11 (0.50) | KIF11GSRGRM8GRM6GRIN2D | |
| Hydrochloric Acid SCHEMBL29213474 | 0.98 | NOS2 (0.50) | KIF11GSRGRM8GRM6GRIN2D | |
| Hydrochloric Acid SCHEMBL319257 | 0.98 | NOS2 (0.50) | KIF11GSRGRM8GRM6GRIN2D | |
| SCHEMBL10052913 | 0.88 | GSR (0.56) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL10052915 | 0.88 | GSR (0.56) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL16497780 | 0.88 | GSR (0.56) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Ammonia Solution, Strong SCHEMBL28728275 | 0.86 | GSR (0.54) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL17431026 | 0.85 | GSR (0.57) | GSRGRM8GRM6GRIN2DGRIN3B | |
| SCHEMBL15222427 | 0.85 | GSR (0.57) | GSRGRM8GRM6GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119061087-A | Synthesis method of (S) -2-amino-5, 5-dimethylhexanoic acid | 四川同晟生物医药有限公司 | 2024-12-03 | — | — | CN | claimed |
| EP-4676914-A1 | MODULATORS OF SORTILIN ACTIVITY | Vesper Bio Aps (DK) | 2026-01-14 | — | — | EP | disclosed |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| US-20250268854-A1 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | VESPER BIO APS (DK) | 2025-08-28 | — | — | US | disclosed |
| CN-120077033-A | Sortilin modulators | 维斯珀生物应用有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2025087397-A1 | LIGANDS FOR EXTRAHEPATIC DELIVERY OF siRNA | RONA BIOSCIENCE, LIMITED (CN) | 2025-05-01 | — | — | WO | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| EP-4486443-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | Vesper Bio Aps (DK) | 2025-01-08 | — | — | EP | disclosed |
| CN-119061087-A | Synthesis method of (S) -2-amino-5, 5-dimethylhexanoic acid | 四川同晟生物医药有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-119061087-A | Synthesis method of (S) -2-amino-5, 5-dimethylhexanoic acid | 四川同晟生物医药有限公司 | 2024-12-03 | — | — | CN | disclosed |
| WO-2017180535-A1 | CHIRAL PEPTIDES | CARNOT, LLC (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-2658857-B1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9351989-B2 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | INHIBITEX, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| US-8540966-B2 | Contrast agents endowed with high relaxivity | BRACCO IMAGING S.P.A. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8105567-B2 | Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy | BRACCO IMAGING SPA (IT) | 2012-01-31 | — | — | US | disclosed |
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | BRACCO IMAGING SPA (IT) | 2011-10-20 | — | — | US | disclosed |
| EP-0692538-B1 | Process for producing optically active L-amino acids | DEGUSSA (DE) | 1999-09-22 | — | — | EP | disclosed |
| EP-0692478-A1 | Process for the preparation of optically active 4 substituted (S)-2-oxazolidinone, optically active (S)-aminoalcohols and utilization of there compounds | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | disclosed |
| EP-0692538-A2 | Process for producing optically active L-amino acids, novel optically active L-aminoacids with bulky side-chains and their use | Degussa Aktiengesellschaft (DE) | 1996-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256067-A1 | Contrast agents endowed with high relaxivity | SLC40A1, SLC67A1, SLC19A1 | KIF11 2945/4885GSR 889/4885GRM8 3388/4885 |
| US-20250268854-A1 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | SORT1, NMUR2, NMUR1 | KIF11 1659/4885GSR 4825/4885GRM8 1797/4885 |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | KIF11 3398/4885GSR 4540/4885GRM8 4061/4885 |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PNP, UMPS, UPP1 | KIF11 4354/4885GSR 1735/4885GRM8 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.